

ASX Announcement

Imugene granted India patent for oncolytic virotherapy CF33

- CF33 patent granted in India, further strengthening global intellectual property protection
- Patent provides method of composition and method of use protection until 2037

SYDNEY, Australia, 27 February 2025: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce the grant of a patent in India for its exclusively licensed CF33 oncolytic virotherapy technology.

Under patent number 558994, the term of this patent is 20 years from the filing date of 9 August 2017, adding to the patent protection in the United States (granted on September 10, 2024, Pat. No. 12,084,687) and Japan (Patent Application No. 2023-200433), both within the same oncolytic patent family.

This newly granted patent reinforces Imugene's commitment to protecting its CF33 oncolytic virotherapy, a chimeric vaccinia poxvirus developed by Professor Yuman Fong, Chair of Surgical Oncology at City of Hope and a leading expert in oncolytic virus research.

Oncolytic viruses are designed to selectively target and destroy cancer cells while simultaneously stimulating the immune system, offering the potential to improve clinical outcomes for patients.

Imugene Managing Director and CEO Leslie Chong said: "The grant of this India patent is another significant step in expanding global protection for CF33, building on our strong foundation in key markets such as the US and Japan. We remain committed to advancing our oncolytic virotherapy pipeline and delivering next-generation immunotherapies to patients worldwide."



For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

info@imugene.com

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and



resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.